-
Encouraging animal model efficacy data has been published in Journal of Ethnopharmacology
-
Clinical trial of 100 patients diagnosed with COVID-19 to begin soon in India
-
TADIOS found to have anti-inflammatory, anti-oxidative activities and therapeutic effects in acute lung injury animal model
January 14, 2021 – Helixmith Co., Ltd. has announced that TADIOS (HX110), a respiratory treatment developed by the company, showed lung damage-suppressing capability in an acute lung injury mouse model. The results have been published in the Journal of Ethnopharmacology. Helixmith plans to conduct a clinical trial in India to assess if TADIOS can be used as a COVID-19 treatment. Helixmith has signed an agreement with a contract research organization (CRO) that has extensive experience and capacities in the conduct of clinical trials in India. The clinical trial will be conducted in accordance with the regulations of the Ministry of AYUSH, India’s traditional medicine regulatory body, and will begin in February with 100 subjects. [Read more…]